RS65347B1 - Imunomodulacija i tretman čvrstih tumora antitelima koja specifično vezuju cd38 - Google Patents
Imunomodulacija i tretman čvrstih tumora antitelima koja specifično vezuju cd38Info
- Publication number
- RS65347B1 RS65347B1 RS20240308A RSP20240308A RS65347B1 RS 65347 B1 RS65347 B1 RS 65347B1 RS 20240308 A RS20240308 A RS 20240308A RS P20240308 A RSP20240308 A RS P20240308A RS 65347 B1 RS65347 B1 RS 65347B1
- Authority
- RS
- Serbia
- Prior art keywords
- antibodies
- treatment
- specifically bind
- solid tumors
- immune modulation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000008102 immune modulation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184018P | 2015-06-24 | 2015-06-24 | |
| US201562249546P | 2015-11-02 | 2015-11-02 | |
| US201562250566P | 2015-11-04 | 2015-11-04 | |
| US201562263307P | 2015-12-04 | 2015-12-04 | |
| US201662331489P | 2016-05-04 | 2016-05-04 | |
| PCT/US2016/039165 WO2016210223A1 (en) | 2015-06-24 | 2016-06-24 | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| EP16815351.8A EP3313441B1 (en) | 2015-06-24 | 2016-06-24 | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65347B1 true RS65347B1 (sr) | 2024-04-30 |
Family
ID=57586547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240308A RS65347B1 (sr) | 2015-06-24 | 2016-06-24 | Imunomodulacija i tretman čvrstih tumora antitelima koja specifično vezuju cd38 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20160376373A1 (sr) |
| EP (1) | EP3313441B1 (sr) |
| JP (2) | JP7041519B2 (sr) |
| KR (1) | KR20180012864A (sr) |
| CN (1) | CN107921120A (sr) |
| AU (1) | AU2016281717B2 (sr) |
| BR (1) | BR112017027990A2 (sr) |
| CA (1) | CA2990620A1 (sr) |
| CL (2) | CL2017003275A1 (sr) |
| CO (1) | CO2017013332A2 (sr) |
| DK (1) | DK3313441T3 (sr) |
| DO (1) | DOP2017000305A (sr) |
| EA (1) | EA037548B1 (sr) |
| EC (1) | ECSP17084878A (sr) |
| FI (1) | FI3313441T3 (sr) |
| GT (1) | GT201700286A (sr) |
| HK (1) | HK1254942A1 (sr) |
| HR (1) | HRP20240338T1 (sr) |
| IL (1) | IL256248A (sr) |
| LT (1) | LT3313441T (sr) |
| MX (3) | MX2018000261A (sr) |
| MY (1) | MY193727A (sr) |
| NI (1) | NI201700170A (sr) |
| PE (1) | PE20181090A1 (sr) |
| PH (1) | PH12017502311A1 (sr) |
| RS (1) | RS65347B1 (sr) |
| SV (1) | SV2017005607A (sr) |
| UA (1) | UA124799C2 (sr) |
| WO (1) | WO2016210223A1 (sr) |
| ZA (1) | ZA201800476B (sr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2567976T1 (sl) * | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
| LT2580243T (lt) | 2010-06-09 | 2020-01-27 | Genmab A/S | Antikūnai prieš žmogaus cd38 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| WO2015145422A1 (en) | 2014-03-26 | 2015-10-01 | Scr Engineers Ltd | Livestock location system |
| UA119167C2 (uk) | 2014-03-28 | 2019-05-10 | Зенкор, Інк. | Біспецифічне антитіло, яке зв'язується з cd38 та cd3 |
| US10986817B2 (en) | 2014-09-05 | 2021-04-27 | Intervet Inc. | Method and system for tracking health in animal populations |
| US11071279B2 (en) | 2014-09-05 | 2021-07-27 | Intervet Inc. | Method and system for tracking health in animal populations |
| MY192918A (en) | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
| CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| AU2016264725B2 (en) | 2015-05-20 | 2021-05-27 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| JP6816038B2 (ja) | 2015-06-22 | 2021-01-20 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| MA53356B1 (fr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations |
| AU2016348391A1 (en) * | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| BR112019014147A2 (pt) * | 2017-01-09 | 2020-02-11 | Biomunex Pharmaceuticals | Ligante polipeptídico para a preparação de anticorpos multiespecíficos |
| KR20190111063A (ko) * | 2017-01-26 | 2019-10-01 | 상가모 테라퓨틱스, 인코포레이티드 | B-세포 조작 |
| AU2018280868A1 (en) | 2017-06-08 | 2020-01-02 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| MX2020010913A (es) | 2018-04-17 | 2021-01-08 | Celldex Therapeutics Inc | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. |
| AU2019261293A1 (en) | 2018-04-22 | 2020-12-10 | Vence, Corp. | Livestock management system and method |
| MA53123A (fr) * | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
| MA53122A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Variants d'anticorps cd38 et leurs utilisations |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| BR112021005525A2 (pt) * | 2018-09-27 | 2021-06-29 | Musc Foundation For Research Development | combinação farmacêutica para o tratamento de câncer |
| CN112911927B (zh) | 2018-10-10 | 2023-06-27 | 世亚工程设备有限公司 | 牲畜干乳方法和装置 |
| WO2020194241A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses |
| MX2022008050A (es) | 2020-01-16 | 2022-07-27 | Genmab As | Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas. |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| USD990063S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
| USD990062S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
| IL275518B (en) | 2020-06-18 | 2021-10-31 | Scr Eng Ltd | Animal tag |
| IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
| WO2022113062A1 (en) | 2020-11-25 | 2022-06-02 | Scr Engineers Ltd. | A system and method for tracing members of an animal population |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| AU2022208200A1 (en) | 2021-01-14 | 2023-07-20 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| CN114805582B (zh) * | 2022-06-29 | 2022-10-04 | 上海恒润达生生物科技股份有限公司 | 抗Trop2纳米抗体及其用途 |
| WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| SG177008A1 (en) | 2003-03-05 | 2012-01-30 | Halozyme Inc | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| WO2004111233A1 (ja) | 2003-06-11 | 2004-12-23 | Chugai Seiyaku Kabushiki Kaisha | 抗体の製造方法 |
| EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
| WO2006125640A2 (en) | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| SI2567976T1 (sl) * | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| AU2006301446B2 (en) | 2005-10-12 | 2012-06-07 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| SI2081595T1 (sl) * | 2006-09-26 | 2019-10-30 | Genmab As | Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| NZ614857A (en) | 2007-03-29 | 2015-04-24 | Genmab As | Bispecific antibodies and methods for production thereof |
| DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
| ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CN102264762B (zh) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
| TWI686405B (zh) | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| RS60033B1 (sr) | 2009-11-24 | 2020-04-30 | Medimmune Ltd | Ciljano vezujući agensi usmereni na b7-h1 |
| BR112012026766B1 (pt) | 2010-04-20 | 2021-11-03 | Genmab A/S | Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| LT2580243T (lt) * | 2010-06-09 | 2020-01-27 | Genmab A/S | Antikūnai prieš žmogaus cd38 |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
| US9212224B2 (en) * | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| EP2878166A1 (en) | 2012-07-24 | 2015-06-03 | Telefonaktiebolaget L M Ericsson (Publ) | Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2914302B1 (en) * | 2012-11-05 | 2017-01-04 | MorphoSys AG | Radiolabelled antibody and uses thereof |
| AU2013388126B2 (en) | 2013-04-29 | 2019-03-07 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b |
| US20140356318A1 (en) * | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| US20160235842A1 (en) * | 2013-07-15 | 2016-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of cd38 agonists |
| EP3066125A2 (en) * | 2013-11-06 | 2016-09-14 | Boehringer Ingelheim International GmbH | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
-
2016
- 2016-06-24 AU AU2016281717A patent/AU2016281717B2/en active Active
- 2016-06-24 MY MYPI2017704935A patent/MY193727A/en unknown
- 2016-06-24 PE PE2017002833A patent/PE20181090A1/es unknown
- 2016-06-24 BR BR112017027990-8A patent/BR112017027990A2/pt active Search and Examination
- 2016-06-24 FI FIEP16815351.8T patent/FI3313441T3/fi active
- 2016-06-24 CN CN201680048975.9A patent/CN107921120A/zh active Pending
- 2016-06-24 HR HRP20240338TT patent/HRP20240338T1/hr unknown
- 2016-06-24 EP EP16815351.8A patent/EP3313441B1/en active Active
- 2016-06-24 UA UAA201800631A patent/UA124799C2/uk unknown
- 2016-06-24 CA CA2990620A patent/CA2990620A1/en active Pending
- 2016-06-24 US US15/191,808 patent/US20160376373A1/en not_active Abandoned
- 2016-06-24 JP JP2017566768A patent/JP7041519B2/ja active Active
- 2016-06-24 RS RS20240308A patent/RS65347B1/sr unknown
- 2016-06-24 MX MX2018000261A patent/MX2018000261A/es unknown
- 2016-06-24 KR KR1020187001612A patent/KR20180012864A/ko not_active Application Discontinuation
- 2016-06-24 WO PCT/US2016/039165 patent/WO2016210223A1/en active Application Filing
- 2016-06-24 DK DK16815351.8T patent/DK3313441T3/da active
- 2016-06-24 EA EA201890131A patent/EA037548B1/ru unknown
- 2016-06-24 LT LTEPPCT/US2016/039165T patent/LT3313441T/lt unknown
-
2017
- 2017-12-11 IL IL256248A patent/IL256248A/en unknown
- 2017-12-14 PH PH12017502311A patent/PH12017502311A1/en unknown
- 2017-12-19 CL CL2017003275A patent/CL2017003275A1/es unknown
- 2017-12-20 NI NI201700170A patent/NI201700170A/es unknown
- 2017-12-21 DO DO2017000305A patent/DOP2017000305A/es unknown
- 2017-12-22 SV SV2017005607A patent/SV2017005607A/es unknown
- 2017-12-22 CO CONC2017/0013332A patent/CO2017013332A2/es unknown
- 2017-12-26 GT GT201700286A patent/GT201700286A/es unknown
- 2017-12-26 EC ECIEPI201784878A patent/ECSP17084878A/es unknown
-
2018
- 2018-01-08 MX MX2021012134A patent/MX2021012134A/es unknown
- 2018-01-08 MX MX2021012133A patent/MX2021012133A/es unknown
- 2018-01-23 ZA ZA2018/00476A patent/ZA201800476B/en unknown
- 2018-11-02 HK HK18114045.6A patent/HK1254942A1/zh unknown
-
2019
- 2019-12-13 CL CL2019003657A patent/CL2019003657A1/es unknown
-
2022
- 2022-02-03 JP JP2022015442A patent/JP2022070892A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254942A1 (zh) | 用特異性結合cd38的抗體免疫調節和治療實體瘤 | |
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
| HK1245171A1 (zh) | 結合cd3和cd38的異二聚體抗體 | |
| IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| HK1244219A1 (zh) | 結合cd3和腫瘤抗原的異二聚體抗體 | |
| IL252480A0 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
| ZA201903848B (en) | Antibodies that specifically bind to human il-15 and uses thereof | |
| IL259713A (en) | Anti-dr5 antibodies and methods of using them | |
| IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
| GB202103867D0 (en) | Claudin6 antibodies and methods of treating cancer | |
| SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |